Our Products
For urgent assistance, please contact emergency response services Call: 911
Product Questions?
Questions, comments, or concerns about Cameron Pharmaceuticals products? Contact one of our trusted professionals today.
Phone: 888.767.7913
Email: inquiry@cameronrx.com
Product List
Acetylcysteine Solution, USP
Overview: Acetylcysteine solution is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as:
-Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung)
-Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis)
-Pulmonary complications of cystic fibrosis
-Tracheostomy care
-Pulmonary complications associated with surgery
-Use during anesthesia
-Post-traumatic chest conditions
-Atelectasis due to mucous obstruction
-Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)
Strengths: 10% and 20%
Package Size: 25 count 4mL Vials
NDC Codes: 42494-435-25; 42494-436-25
TE Rating: Not Applicable
Package Insert: Download
Usage: Acetylcysteine inhalation is used to thin the mucus in people with certain lung conditions such as cystic fibrosis, emphysema, bronchitis, pneumonia, or tuberculosis. Acetylcysteine inhalation is also used during surgery or anesthesia, and to prepare the throat or lungs for a medical test.
Phenobarbital Sodium Injection, USP
Overview: Barbiturates are nonselective central nervous system (CNS) depressants that are primarily used as sedative hypnotics and also anticonvulsants in sub-hypnotic doses.
Strengths: 65mg and 130mg
Package Size: 3 and 25-count packs
NDC Codes: 42494-415-01; 42494-415-03; 42494-415-25; 42494-416-01; 42494-416-03; 42494-416-25
TE Rating: Not Applicable
Package Insert: Download
Usage: a. Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in the treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates.
b. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY).
c. Preanesthetic.
d. Long-term anticonvulsant, (phenobarbital, mephobarbital, and metharbital) for treating generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium, until the convulsions stop, may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression.
e. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use.